Moderna is trading 4% up today at $56.68 as investors position ahead of its Q2 2026 earnings report on July 31 and focus on early commercial traction for its new RSV vaccine, mRESVIA.
- The stock is benefiting from a broad tech-led market rebound, with the Nasdaq Composite up about 2.4%, lifting risk assets across growth and biotech names.
- Market sentiment remains sensitive to upcoming revenue and EPS loss expectations surrounding the company's COVID and RSV franchises.